Brief Summary
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibodya protein made by the immune system to fight against harmful substances (antigens), such as bacteria or viruses targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Intervention / Treatment
- Drug: AZD5492
Inclusion Criteria:
- ≥18 years of age;
- Histologically documented CD20+ mature B-cell neoplasm
- Large B-cell lymphomacancers of the lymphatic system
- Follicular lymphoma
- Mantle cell lymphoma
- Chronica long-lasting disease that changes slowly over time lymphocytic leukemia
- Small lymphocytic lymphoma
- Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy;
- ECOG performance status of ≤ 2.
The above is a summary, other inclusion criteria details may apply.